Audentes Therapeutics, Inc. announced the continued expansion of its leadership team, including the appointment of John T. Gray, Ph.D., as Vice President, Research and Development. Dr. Gray brings more than 20 years of gene therapy research and manufacturing experience to Audentes. In addition to Dr. Gray, Audentes has appointed Mary Newman as Senior Vice President, Regulatory Affairs and Dawn Blessing as Vice President, Corporate Development.

John T. Gray joins Audentes with over 20 years of experience designing genetic therapies and vaccines, and developing manufacturing processes for those products. Ms. Newman brings over 25 years of experience in regulatory affairs, and research and development, within the biotechnology industry. She joins Audentes after serving 7 years at SARcode Inc. (acquired by Shire Ltd.), most recently as Senior Vice President, Regulatory Affairs and Quality Assurance.

Ms. Newman's responsibilities included oversight of global regulatory strategic development, all primary regulatory agency interactions, and quality assurance for SARcode products.